用于治疗哮喘和慢性阻塞性气道疾病（COPD）的吸入器装置。
Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD).
作者信息
Wright J, Brocklebank D, Ram F
机构信息
Department of Epidemiology and Public Health, Bradford Hospitals NHS Trust, Royal Infirmary, Bradford BD9 6RJ, UK.
出版信息
Qual Saf Health Care. 2002 Dec;11(4):376-82. doi: 10.1136/qhc.11.4.376.
Abstract
The research evidence on the effectiveness of inhaler devices for the treatment of asthma and chronic obstructive pulmonary disease published in a recent issue of Effective Health Care is reviewed.
摘要
对近期一期《有效医疗保健》上发表的关于吸入器装置治疗哮喘和慢性阻塞性肺疾病有效性的研究证据进行了综述。
相似文献
1
Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD).用于治疗哮喘和慢性阻塞性气道疾病（COPD）的吸入器装置。
Qual Saf Health Care. 2002 Dec;11(4):376-82. doi: 10.1136/qhc.11.4.376.
2
Changes in inhaler devices for asthma and COPD.用于哮喘和慢性阻塞性肺疾病的吸入器装置的变化。
Medsurg Nurs. 2005 Jun;14(3):185-94.
3
Triple inhalers for obstructive airways disease: will they be useful?用于阻塞性气道疾病的三联吸入器：它们会有用吗？
Expert Rev Respir Med. 2011 Jun;5(3):297-300. doi: 10.1586/ers.11.26.
4
Cost saving of switching to equivalent inhalers and its effect on health outcomes.转换等效吸入器的成本节约及其对健康结果的影响。
Thorax. 2019 Nov;74(11):1078-1086. doi: 10.1136/thoraxjnl-2018-212957. Epub 2019 Aug 5.
5
Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey.阻塞性肺病和吸入器治疗：来自全国性公共实用主义调查的结果。
Respir Res. 2013 Sep 22;14(1):94. doi: 10.1186/1465-9921-14-94.
6
[Asthma and COPD: guidance in the jungle of inhalative drugs].[哮喘与慢性阻塞性肺疾病：吸入药物丛林中的指南]
MMW Fortschr Med. 2015 May 28;157(10):59, 61-2. doi: 10.1007/s15006-015-3139-6.
7
Advances in Audio-Based Systems to Monitor Patient Adherence and Inhaler Drug Delivery.基于音频的系统在监测患者依从性和吸入器药物输送方面的进展。
Chest. 2018 Mar;153(3):710-722. doi: 10.1016/j.chest.2017.08.1162. Epub 2017 Sep 5.
8
Treating the small airways.治疗小气道。
Respiration. 2012;84(6):441-53. doi: 10.1159/000343629. Epub 2012 Nov 15.
9
[Recommendations for nebulizer therapy].[雾化治疗的建议]
Rev Mal Respir. 2002 Feb;19(1):87-9.
10
[Persistence to treatment by type of inhaler device in patients with asthma and chronic obstructive pulmonary disease].[哮喘和慢性阻塞性肺疾病患者按吸入器装置类型划分的治疗依从性]
Semergen. 2017 Jul-Aug;43(5):375-386. doi: 10.1016/j.semerg.2016.05.008. Epub 2016 Jul 16.
引用本文的文献
1
Predictive machine learning algorithm for COPD exacerbations using a digital inhaler with integrated sensors.使用带有集成传感器的数字吸入器的慢性阻塞性肺疾病（COPD）急性加重预测机器学习算法。
BMJ Open Respir Res. 2025 May 12;12(1):e002577. doi: 10.1136/bmjresp-2024-002577.
2
Misuse of Respiratory Inhalers Among Hospitalized Patients in a Tertiary Health Care Hospital in Kabul.喀布尔一家三级保健医院住院患者中呼吸吸入器的误用情况。
Int J Chron Obstruct Pulmon Dis. 2023 Mar 18;18:365-371. doi: 10.2147/COPD.S396019. eCollection 2023.
3
A Predictive Machine Learning Tool for Asthma Exacerbations: Results from a 12-Week, Open-Label Study Using an Electronic Multi-Dose Dry Powder Inhaler with Integrated Sensors.一种用于哮喘急性加重的预测性机器学习工具：使用带有集成传感器的电子多剂量干粉吸入器进行的为期12周的开放标签研究结果。
J Asthma Allergy. 2022 Nov 11;15:1623-1637. doi: 10.2147/JAA.S377631. eCollection 2022.
4
Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary after COVID-19 Infection.新冠后综合征：新型冠状病毒感染后肺部治疗的研究进展
Pharmaceutics. 2022 May 26;14(6):1135. doi: 10.3390/pharmaceutics14061135.
5
Critical Inhaler Administration Errors of Patients on Pressurized Meter Dose Inhaler (pMDI): A Hospital-Based Cross-Sectional Study in Malaysia.压力定量吸入器（pMDI）患者的严重吸入器使用错误：马来西亚一项基于医院的横断面研究
Hosp Pharm. 2022 Apr;57(2):217-222. doi: 10.1177/00185787211010164. Epub 2021 Apr 21.
6
The effectiveness of large group demonstration training method on the use of pressurized metered-dose inhaler in elderly with chronic obstructive pulmonary disease.大组示范训练法对老年慢性阻塞性肺疾病患者使用压力定量吸入器的效果研究
J Thorac Dis. 2022 Apr;14(4):919-926. doi: 10.21037/jtd-21-1612.
7
Butyrate and Propionate Restore the Cytokine and House Dust Mite Compromised Barrier Function of Human Bronchial Airway Epithelial Cells.丁酸和丙酸可恢复细胞因子及屋尘螨破坏的人支气管气道上皮细胞屏障功能。
Int J Mol Sci. 2020 Dec 23;22(1):65. doi: 10.3390/ijms22010065.
8
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD.在 COPD 治疗中，领先的有许可的 ICS/LABA 联合吸入器的真实临床疗效比较。
Int J Chron Obstruct Pulmon Dis. 2020 Nov 26;15:3093-3103. doi: 10.2147/COPD.S263745. eCollection 2020.
9
Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes.呼吸系统疾病的吸入疗法：肺动力学过程的复杂相互作用
Can Respir J. 2018 Jun 19;2018:2732017. doi: 10.1155/2018/2732017. eCollection 2018.
10
Inhaled sGC Modulator Can Lower PH in Patients With COPD Without Deteriorating Oxygenation.吸入型可溶性鸟苷酸环化酶激动剂可降低 COPD 患者的 PH 值而不恶化氧合。
CPT Pharmacometrics Syst Pharmacol. 2018 Aug;7(8):491-498. doi: 10.1002/psp4.12308. Epub 2018 Jul 2.
本文引用的文献
1
Comparison of Pulmicort pMDI plus Nebuhaler and Pulmicort Turbuhaler in asthmatic patients with dysphonia.布地奈德压力定量气雾剂加吸乐与都保在患有发声困难的哮喘患者中的比较。
Respir Med. 2000 May;94(5):448-53. doi: 10.1053/rmed.1999.0762.
2
Efficacy and safety of a novel beclomethasone dipropionate dry powder inhaler (Clickhaler) for the treatment of adult asthma. Amsterdam Clinical Study Group.一种新型丙酸倍氯米松干粉吸入器（Clickhaler）治疗成人哮喘的疗效和安全性。阿姆斯特丹临床研究小组。
J Asthma. 2000 Apr;37(2):183-90. doi: 10.3109/02770900009055441.
3
Equivalence of two steroid-containing inhalers: easyhaler multidose powder inhaler compared with conventional aerosol with large-volume spacer.两种含类固醇吸入器的等效性：易吸乐多剂量粉末吸入器与带大容量储雾罐的传统气雾剂的比较。
Respiration. 2000;67(2):194-202. doi: 10.1159/000029486.
4
Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma.通过易呼吸吸入器递送的含氯氟烃和不含氯氟烃（氢氟烷烃134a）推进剂的丙酸倍氯米松吸入剂在治疗儿童哮喘方面的治疗等效性。
Respir Med. 2000 Jan;94(1):57-63. doi: 10.1053/rmed.1999.0678.
5
Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers.改用不含氯氟烃的吸入性糖皮质激素：HFA-倍氯米松二丙酸酯和CFC-倍氯米松二丙酸酯定量气雾剂的疗效对比研究。
Int J Clin Pract. 1999 Jul-Aug;53(5):331-8.
6
Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant.吸入用丙酸倍氯米松治疗哮喘的疗效反应与剂量成正比，且采用新型推进剂的剂型可提高疗效。
J Allergy Clin Immunol. 1999 Dec;104(6):1215-22. doi: 10.1016/s0091-6749(99)70016-3.
7
Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography.氢氟烷烃和氯氟烃丙酸倍氯米松吸入剂对小气道的比较效应：使用功能性螺旋薄层计算机断层扫描进行评估
J Allergy Clin Immunol. 1999 Dec;104(6):S258-67. doi: 10.1016/s0091-6749(99)70043-6.
8
Health-related quality of life in moderate asthma: 400 microg hydrofluoroalkane beclomethasone dipropionate vs 800 microg chlorofluorocarbon beclomethasone dipropionate. The Study Group.中度哮喘患者的健康相关生活质量：400微克氢氟烷烃倍氯米松二丙酸酯与800微克氯氟碳倍氯米松二丙酸酯的比较。研究组
Chest. 1999 Nov;116(5):1297-303. doi: 10.1378/chest.116.5.1297.
9
A cost analysis on the pattern of asthma prescribing in the UK.英国哮喘处方模式的成本分析。
Eur Respir J. 1999 Sep;14(3):605-9. doi: 10.1034/j.1399-3003.1999.14c20.x.
10
Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma.使用非氯氟烃推进剂（氢氟烷烃134a）的吸入用倍氯米松（BDP）在治疗哮喘方面与含氯氟烃的BDP等效。
Respir Med. 1999 Apr;93(4):245-51. doi: 10.1016/s0954-6111(99)90020-3.
Zotero 插件